Sep 2026
Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study.
The persistence at 1 year from switch to SC-VDZ in IBD patients was 84%, and Vedolizumab drug levels were similar between persistent and non-persistent patients throughout the study period.
Marianne Hupé, Nicolas Mathieu, A. Amiot et al.
· Alimentary Pharmacology and... · 2 citations